Trial Profile
One-arm, single-center, open phase II clinical study of CART-19 cells in the treatment of relapsed/refractory B cell leukemia/lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapy-Henan-Huarong-Biotechnology (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2018 New trial record